PALO ALTO, Calif., Jan. 30 /PRNewswire/ -- The U.S. pulmonary arterial hypertension (PAH) markets present a mix of challenges and opportunities and are likely to provide pharmaceutical and biotechnology market participants prospects to develop improved therapies and diagnostic tools. The rapid growth of this market has captured the attention of industry participants across tiers of competition resulting in a strong pipeline of products.
"The increased interest from 'big pharma' companies combined with the launch of new and improved therapies is likely to increase market penetration and drive growth," notes Frost & Sullivan Research Analyst Barath Shankar S.
Pharmaceutical and biotechnology companies have evinced interest in the PAH markets despite the small patient population. The robust late stage drug pipeline has resulted in in-licensing deals and M&A activity.
Due to a lack of awareness about the disease, the rate of diagnosis and treatment is low, resulting in higher mortality rate among patients diagnosed at a late-stage of the disease.
"The average survival time of patients upon diagnosis is between 3-4 years chiefly due to the low diagnosis rates," says Barath Shankar. "Several patients are unaware of the existence of the disease until progression to a chronic stage."
Several leading pharmaceutical and biotechnology companies have shown interest in this market. The development of improved therapies, combined with increased awareness is likely to enable the growth of this market.
U.S. Pulmonary Arterial Hypertension Markets is part of the Pharmaceuticals and Biotechnology subscription, which also includes research in the following markets: U.S. drug discovery contract research organization markets, analysis of Top 10 specialty pharmaceutical companies, and global vaccines markets. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Interviews with the press are available.
Keywords: PAH, U.S., Pulmonary Arterial Hypertension, therapies, diagnostic tools, pharmaceutical, biotechnology, big pharma, research, information, market, trends, technology, service, forecast, market share
Frost & Sullivan
